Here is the design of a clinical trial:

Official Title: Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON)

Included conditions:
- Colon Cancer

Study Armgroups:
- {'label': 'D2 lymph node dissection for right colon cancer', 'type': 'ACTIVE_COMPARATOR', 'description': 'Hemicolectomy for right colon cancer with D2 lymph node dissection', 'interventionNames': ['Procedure: Right Hemicolectomy with D2 lymph node dissection']}
- {'label': 'D3 lymph node dissection for right colon cancer', 'type': 'EXPERIMENTAL', 'description': 'Hemicolectomy for right colon cancer with D3 lymph node dissection', 'interventionNames': ['Procedure: Right Hemicolectomy with D3 lymph node dissection']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'Right Hemicolectomy with D2 lymph node dissection', 'description': 'Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).', 'armGroupLabels': ['D2 lymph node dissection for right colon cancer']}
- {'type': 'PROCEDURE', 'name': 'Right Hemicolectomy with D3 lymph node dissection', 'description': 'Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).', 'armGroupLabels': ['D3 lymph node dissection for right colon cancer']}

Primary Outcomes:
- {'measure': '5-year survival', 'description': 'death from any cause', 'timeFrame': 'Up to 5 years post-operative'}

Please estimate the sample size based on the assumption: 
The power of the study is set at 80%, with a type I error of 5%. An expected loss of follow-up is estimated at 15% for patients in each group. The enrollment period for patients is 3 years, and the total duration of the study will be 8 years.
Sample size calculation
        According to the SEER database (2004â2012) and AJCC 5th, 6th, and 7th editions, the 5-year overall survival for stage II right colon cancer was 68â84%, and for stage III, it was approximately 57 to 60% [21â23]. In the JCOG0404 trial, the 5-year overall survival for stage II-III was 91% [24]. Literature data suggests that the baseline survival for D2 lymph node dissection group is estimated to be 75% for stage II-III of the disease, and for D3 group, it is 90%, respectively. An anticipated difference of 15% in 5-year overall survival between D2 and D3 LND groups is expected. The log-rank test (Lacatos, proportion of surviving) was utilized in the PASS 11 program for sample size calculation. The power of the study is set at 80%, with a type I error 5%. An expected loss of follow-up is estimated at 15% for patients in each group. The enrollment period for patients is 3Â years, and the total duration of the study will be 8Â years. Based on aforementioned conditions, 239 patients should be included in the study (Table 1). Ultimately, 120 patients will be included in D3 group, and 119 patients in D2 group. The anticipated number of deaths in the D2 group is 24, and in the D3 group, it is 10.
        
Table 1Sample size calculation